Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: A follow up study in an independent laboratory

Journal of Neurology Neurosurgery and Psychiatry

Volumn 73, Issue 2, 2002, Pages 148-153

  Bertolotto, A ^a   Malucchi, S ^a   Sala, A ^a   Orefice, G ^b   Carrieri, P B ^b   Capobianco, M ^a   Milano, E ^a   Melis, F ^a   Giordana, M T ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; INTERFERON BETA SERINE; NEUTRALIZING ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL;

ADULT; ANTIBODIES; ANTIBODY SPECIFICITY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUTRALIZATION TESTS;

EID: 0036329631     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.73.2.148     Document Type: Article

References (32)

1. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years
2. Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis
3. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis
4. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis
5. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS
6. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration
7. IFNbeta bioavailability in multiple sclerosis patients: MxA mRNA quantification by competitive RT-PCR
8. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies
9. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
10. Changes in serum slCAM-1 and MMP-9 induced by rlFNbeta-1b treatment in relapsing-remitting MS
11. Correlation of the appearance of anti-interferon antibodies during treatment and diminution of efficacy: Summary of an international workshop on anti-interferon antibodies
12. Neutralizing antibodies reduce IFN beta efficacy in multiple sclerosis patients: A 3 year follow-up study in 66 multiple sclerosis patients
13. Interferon β neutralizing antibodies in multiple sclerosis: Neutralizing activity and cross-reactivity with three different preparations
14. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: Plight of the practicing neurologist
15. Neutralizing antibodies to interferon-β in the treatment of multiple sclerosis: Cause for concern?
16. Interferon-neutralizing antibodies reduce clinical and magnetic resonance imaging efficacy in multiple sclerosis patients treated with interferon β-1a (Rebif): Observations from the PRISMS 4-year extension study
17. Incidence of antibodies to interferon beta in patients treated with recombinant human interferon beta-1a from mammalian cells
18. Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-β 1a
19. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b
20. Neutralizing and binding anti-interferon-β (IFN-β) antibodies: A comparison between IFN-β-1a and IFN-β1b treatment in multiple sclerosis
21. Immunogenicity of interferon-β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration
22. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
23. Defining the clinical course of multiple sclerosis: Results of an international survey
24. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
25. Quantitation of neutralization of interferon by antibody
26. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial
27. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: Pilot study analysis and six-year follow-up
28. Neutralizing antibodies to interferon (IFN) alpha-2a and IFN beta-1a or IFN beta-1b in MS are not cross-reactive
29. Evidence of interferon β-1a dose response in relapsing-remitting MS
30. Structural and functional differences between glycosylated and non-glycosylated farms of human interferon-β (IFN-β)
31. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis